Table V.
Normalization Methodology | PLVH (%) | 2D CMR | Echocardiography | |||||||
---|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||
BSA | height1.7 | height2.7 | %predicted | BSA | height1.7 | height2.7 | %predicted | |||
2D CMR | BSA | 5.5 | * | 0.41† | 0.44† | 0.76† | 0.37† | 0.11§ | 0.29† | 0.44† |
height1.7 | 3.4 | 93% | * | 0.61† | 0.37† | 0.23¥ | 0.23† | 0.23¥ | 0.23¥ | |
height2.7 | 6.8 | 94% | 95% | * | 0.55† | 0.33† | 0.14¥ | 0.36† | 0.25† | |
%predicted | 6.2 | 98% | 94% | 96% | * | 0.42† | 0.10§ | 0.34† | 0.59† | |
Echo | BSA | 11.6 | 90% | 87% | 89% | 92% | * | 0.41† | 0.53† | 0.42† |
height1.7 | 24.0 | 77% | 79% | 77% | 77% | 82% | * | 0.41† | 0.20† | |
height2.7 | 7.5 | 92% | 90% | 92% | 93% | 92% | 84% | * | 0.34† | |
%predicted | 3.4 | 95% | 92% | 93% | 97% | 92% | 79% | 93% | * |
CMR – Cardiac Magnetic Resonance; BSA – body-surface area; Echo – echocardiography; PLVH – Prevalence of left ventricular hypertrophy; %predicted - percent of the predicted LVM from a reference group of healthy subjects.
p < 0.001,
p ≤0.01 and
p < 0.05 for test of null hypothesis that kappa=0